QuVa Pharma, Inc.

Form 483 issued October 28, 2024 · Sugar Land, Texas

Inspection
Sep 24 – Oct 28, 2024
Investigator
Camerson E. Moore
Observations
4
Pages
8
FEI number
3012053582

In short: On October 28, 2024, FDA issued a Form 483 with 4 observations to QuVa Pharma, Inc. in Sugar Land, Texas (FEI 3012053582) after an inspection that ran Sep 24 – Oct 28, 2024. The investigator was Camerson E. Moore. Most observations concern production and quality system.

At a glance

Production and quality system account for 4 of 4 observations.

Production2
Quality system2

What FDA observed

Preview: the opening words of each observation
  1. 01

    Procedures designed to prevent microbiological contamination of drug products purporting to be…

  2. 02

    Complaint records are deficient in that they do not include the…

  3. 03

    The responsibilities and procedures applicable to the quality control unit…

  4. 04

    Your firm failed to establish adequate written procedures for production and process controls designed to assure…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at QuVa Pharma, Inc.?

FDA listed 4 observations on this Form 483, mostly about production and quality system. The opening words of each observation are shown on this page.

Who inspected QuVa Pharma, Inc.?

Camerson E. Moore is named on this Form 483, for the inspection of Sep 24 – Oct 28, 2024. Each investigator has a profile showing what they cite most.

When was QuVa Pharma, Inc. inspected by FDA?

The inspection ran Sep 24 – Oct 28, 2024, and the Form 483 is dated October 28, 2024.

How do I get the full Form 483 for QuVa Pharma, Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free